These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Gene expression profile associated with superimposed non-alcoholic fatty liver disease and hepatic fibrosis in patients with chronic hepatitis C. Younossi ZM; Afendy A; Stepanova M; Hossain N; Younossi I; Ankrah K; Gramlich T; Baranova A Liver Int; 2009 Oct; 29(9):1403-12. PubMed ID: 19515216 [TBL] [Abstract][Full Text] [Related]
10. New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Ali R; Cusi K Ann Med; 2009; 41(4):265-78. PubMed ID: 19353360 [TBL] [Abstract][Full Text] [Related]
15. Iron overload is associated with hepatic oxidative damage to DNA in nonalcoholic steatohepatitis. Fujita N; Miyachi H; Tanaka H; Takeo M; Nakagawa N; Kobayashi Y; Iwasa M; Watanabe S; Takei Y Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):424-32. PubMed ID: 19190144 [TBL] [Abstract][Full Text] [Related]
18. PPARgamma inhibits NF-kappaB-dependent transcriptional activation in skeletal muscle. Remels AH; Langen RC; Gosker HR; Russell AP; Spaapen F; Voncken JW; Schrauwen P; Schols AM Am J Physiol Endocrinol Metab; 2009 Jul; 297(1):E174-83. PubMed ID: 19417127 [TBL] [Abstract][Full Text] [Related]
19. The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis. Cariou B Diabetes Metab; 2008 Dec; 34(6 Pt 2):685-91. PubMed ID: 19195631 [TBL] [Abstract][Full Text] [Related]
20. Curcumin ameliorates hepatic fibrosis in type 2 diabetes mellitus - insights into its mechanisms of action. Stefanska B Br J Pharmacol; 2012 Aug; 166(8):2209-11. PubMed ID: 22452372 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]